Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
96% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. GTXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GTXI' s 10-Year Cash to Debt Range
Min: 1890.4  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
92% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GTXI' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -12.79
M-Score: -4.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -193.65
GTXI's ROE (%) is ranked lower than
90% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. GTXI: -193.65 )
Ranked among companies with meaningful ROE (%) only.
GTXI' s 10-Year ROE (%) Range
Min: -397.59  Med: -53.73 Max: 71.17
Current: -193.65
-397.59
71.17
ROA (%) -103.58
GTXI's ROA (%) is ranked lower than
87% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. GTXI: -103.58 )
Ranked among companies with meaningful ROA (%) only.
GTXI' s 10-Year ROA (%) Range
Min: -156.26  Med: -49.45 Max: 25.08
Current: -103.58
-156.26
25.08
ROC (Joel Greenblatt) (%) -57181.82
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. GTXI: -57181.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GTXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -43046.81  Med: -2144.48 Max: 522.64
Current: -57181.82
-43046.81
522.64
Revenue Growth (3Y)(%) -100.00
GTXI's Revenue Growth (3Y)(%) is ranked lower than
92% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GTXI: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GTXI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 98.3
Current: -100
0
98.3
EBITDA Growth (3Y)(%) -15.40
GTXI's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. GTXI: -15.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GTXI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -15.40 Max: 10.5
Current: -15.4
0
10.5
EPS Growth (3Y)(%) -7.20
GTXI's EPS Growth (3Y)(%) is ranked lower than
52% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. GTXI: -7.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GTXI' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.8  Med: -4.90 Max: 192.4
Current: -7.2
-54.8
192.4
» GTXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GTXI Guru Trades in Q2 2014

George Soros 38,828 sh (New)
Paul Tudor Jones 44,285 sh (unchged)
» More
Q3 2014

GTXI Guru Trades in Q3 2014

George Soros Sold Out
Paul Tudor Jones 36,708 sh (-17.11%)
» More
Q4 2014

GTXI Guru Trades in Q4 2014

Paul Tudor Jones 34,033 sh (-7.29%)
» More
Q1 2015

GTXI Guru Trades in Q1 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.26
GTXI's P/B is ranked lower than
87% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. GTXI: 14.26 )
Ranked among companies with meaningful P/B only.
GTXI' s 10-Year P/B Range
Min: 0.44  Med: 4.60 Max: 32.88
Current: 14.26
0.44
32.88
Current Ratio 1.52
GTXI's Current Ratio is ranked lower than
81% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. GTXI: 1.52 )
Ranked among companies with meaningful Current Ratio only.
GTXI' s 10-Year Current Ratio Range
Min: 1.52  Med: 6.48 Max: 21.23
Current: 1.52
1.52
21.23
Quick Ratio 1.52
GTXI's Quick Ratio is ranked lower than
77% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GTXI: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
GTXI' s 10-Year Quick Ratio Range
Min: 1.52  Med: 6.48 Max: 21.22
Current: 1.52
1.52
21.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.70
GTXI's Price/Net Cash is ranked lower than
69% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. GTXI: 15.70 )
Ranked among companies with meaningful Price/Net Cash only.
GTXI' s 10-Year Price/Net Cash Range
Min: 2.7  Med: 6.84 Max: 307.67
Current: 15.7
2.7
307.67
Price/Net Current Asset Value 14.27
GTXI's Price/Net Current Asset Value is ranked lower than
69% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. GTXI: 14.27 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GTXI' s 10-Year Price/Net Current Asset Value Range
Min: 2.64  Med: 6.00 Max: 76.92
Current: 14.27
2.64
76.92
Price/Tangible Book 14.27
GTXI's Price/Tangible Book is ranked lower than
81% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. GTXI: 14.27 )
Ranked among companies with meaningful Price/Tangible Book only.
GTXI' s 10-Year Price/Tangible Book Range
Min: 2.6  Med: 5.81 Max: 43.95
Current: 14.27
2.6
43.95
Earnings Yield (Greenblatt) (%) -15.06
GTXI's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. GTXI: -15.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GTXI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -16.36  Med: 20.30 Max: 3978.9
Current: -15.06
-16.36
3978.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GTU.Germany,
GTx Inc is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company's most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.
» More Articles for GTXI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx, Inc. Reports Second Quarter 2009 Corporate Results Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 
GTX Reports Fourth Quarter and Year End 2008 Results Feb 17 2009 

More From Other Websites
Can the Uptrend Continue for GTx (GTXI)? - Tale of the Tape Jun 30 2015
Edited Transcript of GTXI earnings conference call or presentation 8-May-15 1:00pm GMT Jun 23 2015
AORUS X5 Earth’s Most Powerful Slim Gaming Laptop Jun 18 2015
Can The Uptrend Continue for GTx (GTXI)? - Tale of the Tape Jun 09 2015
GIGABYTE Unveils New ULTRAFORCE Laptops with 5th Gen Intel processor & NVIDIA ... Jun 02 2015
GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 02 2015
GTx Regains Compliance with NASDAQ Bid Price Requirement Jun 02 2015
GTx Regains Compliance with NASDAQ Bid Price Requirement Jun 02 2015
GTx Announces Webcast of Corporate Presentation at Jefferies 2015 Global Healthcare Conference May 26 2015
10-Q for GTx, Inc. May 17 2015
GTX INC /DE/ Financials May 16 2015
GTx (GTXI) Shares March Higher, Can It Continue? - Tale of the Tape May 13 2015
GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2015 May 12 2015
GTX INC /DE/ Files SEC form 10-Q, Quarterly Report May 11 2015
GTX Inc Earnings Call scheduled for 9:00 am ET today May 08 2015
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2015
GTx reports 1Q loss May 08 2015
GTx reports 1Q loss May 08 2015
Q1 2015 GTX Inc Earnings Release - Before Market Open May 08 2015
GTx Provides Corporate Update and Reports First Quarter 2015 Financial Results May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK